On 17 July 2012, orphan designation (EU/3/12/1023) was granted by the European Commission to Aptiv Solutions (UK) Limited, United Kingdom, for metreleptin for the treatment of Barraquer-Simons syndrome.
The sponsorship was transferred to Bristol-Myers Squibb / AstraZeneca EEIG, United Kingdom, in February 2014 then to AstraZeneca AB, Sweden, in April 2014 and subsequently to Aegerion Pharmaceuticals Limited, United Kingdom, in March 2015.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
- What is Barraquer-Simons syndrome?
Barraquer-Simons syndrome (also known as acquired partial lipodystrophy) is a condition characterised by a lack of subcutaneous (under the skin), adipose (fatty) tissue in some parts of the body, especially the upper part.
Patients with Barraquer-Simons syndrome usually develop loss of fat during childhood or adolescence. Fat loss is gradual over a period of a few months to a few years and usually starts in the face and spreads to the neck, arms and thorax. The disease leads to severe complications, including high levels of fats called triglycerides circulating in the blood, insulin resistance (when the body is unable to recognise insulin, a hormone that helps regulate blood sugar levels), diabetes, liver cirrhosis and pancreatitis.
Barraquer-Simons syndrome is a long-term debilitating and life-threatening condition because of its severe complications, including diabetes, hypertriglyceridemia (high blood triglyceride levels) and acute pancreatitis (inflammation of the pancreas).
- What is the estimated number of patients affected by the condition?
At the time of designation, Barraquer-Simons syndrome affected approximately 0.1 in 10,000 people in the European Union (EU). This was equivalent to a total of around 5,100 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 509,000,000 (Eurostat 2012).
- What treatments are available?
At the time of designation, no methods were authorised in the EU for the treatment of Barraquer-Simons syndrome. Patients with the condition were advised to follow a low-fat diet.
- How is this medicine expected to work?
Metreleptin is similar to a human hormone called leptin, which plays a key role in regulating body fat. In Barraquer-Simons syndrome, metreleptin is expected to increase fat breakdown in the blood, muscles and liver, and improve insulin function, thereby correcting some abnormalities in patients with this condition such as insulin resistance. However, the medicine is not expected to restore adipose tissue.
Metreleptin is made by a method known as ‘recombinant DNA technology’: it is made by bacteria that have received a gene (DNA) which makes them able to produce metreleptin.
- What is the stage of development of this medicine?
The effects of metreleptin have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with metreleptin including patients with Barraquer-Simons syndrome were ongoing.
At the time of submission, metreleptin was not authorised anywhere in the EU for Barraquer-Simons syndrome. Orphan designation of metreleptin had been granted in the United States of America for metabolic disorders secondary to lipodystrophy.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 13 June 2012 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/12/1023: Public summary of opinion on orphan designation: Metreleptin for the treatment of Barraquer-Simons syndrome||(English only)||31/08/2012||13/05/2015|
|Disease/condition||Treatment of Barraquer-Simons syndrome|
|Date of decision||17/07/2012|
|Orphan decision number||EU/3/12/1023|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details:
Aegerion Pharmaceuticals Limited
1 Furzeground Way
Stockley Park East
Uxbridge UB11 1BD
Tel. +44 208 622 4100
Fax +44 208 622 3592
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.